On November 4, GENFLEET-B rose 5.17% in Regular Trading, trading at HK$19.74 with turnover of HK$31.71 million.
The move followed the company’s announcement that since the third quarter, multiple innovative combination therapies involving its oral pan-RAS inhibitor GFH276 have received clinical trial clearances from China’s drug regulator or completed trial filings with Australia’s regulator, supporting studies in major RAS-mutant tumor types across both first-line and later-line settings.
The disclosed program update indicates that some of these studies have already enrolled patients across multiple dose levels. Market attention was also supported by broker commentary highlighting encouraging first-in-human data for GFH276, including a 41% ORR in PDAC and a 14.8% rate of grade 3 or higher TRAEs, reinforcing the asset’s potential competitiveness in pan-RAS inhibition. Separately, the company announced on November 3 that it repurchased 101,000 shares for about HK$1.91 million, adding to recent buyback activity.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments